Over the past year, an increasing number of patients and healthcare providers have been turning their attention to Trulicity injection for managing type 2 diabetes. With an increasing number of people ...
- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...
TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...
INDIANAPOLIS, Dec. 1, 2015 /CNW/ -- New data from a completed Phase 3 trial show Trulicity ® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a ...
-- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...
Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with ...
We’ve been following the development of Lilly’s Trulicity (dulaglutide), a once-weekly GLP-1 receptor agonist, for almost two years now, so it was encouraging to hear an update on the drug at ADA last ...
Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback